---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004118"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:50:07.730134+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development

## Summary
- Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.
- Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.
- Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.
- Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.
- Previous 2024 facility agreement also exists; new loan is separate.

## SEC filing metadata
- accession: 0001171843-25-004118
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/0001171843-25-004118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/f8k_062625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004118
- JSON: https://secwatch.observer/filing/0001171843-25-004118.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004118.txt

## Key facts
- Debt Financings
  Aptose Biosciences Inc. incurred credit facility of up to US$8.5 million with Hanmi Pharmaceutical Co. Ltd. at six percent (6%) per annum maturing August 31, 2028.
  - Instrument: credit facility
  - Principal: up to US$8.5 million
  - Counterparty: Hanmi Pharmaceutical Co. Ltd.
  - Rate: six percent (6%) per annum
  - Maturity: August 31, 2028
  - Event: incurrence
  source text: On June 20, 2025, Aptose Biosciences Inc., as borrower (the “Company”), announced that it had entered into a loan agreement (the “Loan Agreement”) with Hanmi Pharmaceutical Co. Ltd., as lender (“Hanmi”). The Loan Agreement is an uncommitted facility for up to US$8.5 million (the “Facility”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/0001171843-25-004118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.